Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Dale Baker who wrote (753)	4/17/1999 8:32:00 PM
From: alf	Read Replies (1) \| Respond to of 10293

about mchm--financial analysis based on past price to sales or anything else has nothing to do with the valuation on this company. If the managment is conning the stockholders, then yes--the company is near worthless. On the other hand, if the company really has a urologist who is telling the truth, then the product has a potential rivaling Viagra. Certainly transdermal systems can work--look at nitroglycerin, estrogens, nicotine, fentynl, etc. The problem is that if there is a blockbuster drug here, the company has been very slow to turn it into its potential; this, plus the history of delays and time to closure on contracts that keeps being pushed back makes for nervousness in anyone holding this stock--such as myself. But the downside is about to about 3; the upside to about 20, maybe more. Dicey. If someone knows that there is chicanery afoot, please post. Thanks